#Gene_accession	TypeGene	Mutation ID	Codon_pos	Ref_nuc	Ref_codon	Res_codon	Class	Phenotype	PMID	Mechanism of resistance	Notes	Required mutation	% abundance mutation required
gyrA_1_CP073768.1	AA	ALA-51	51	GCC	A	V	Quinolone	Nalidixic acid	11451702	Target modification
gyrA_1_CP073768.1	AA	ALA-67	67	GCC	A	S	Quinolone	Nalidixic acid	2168148	Target modification
gyrA_1_CP073768.1	AA	GLY-81	81	GGT	G	C,D	Quinolone	Ciprofloxacin	2168148,8392306	Target modification	G81D mutation confers resistance to ciprofloxacin only. If G81D and D82G are present simultaneously, there is also nalidixic acid resistance
gyrA_1_CP073768.1	AA	GLY-81	81	GGT	G	C,D	Quinolone	Nalidixic acid,Ciprofloxacin	2168148,8392306	Target modification	G81D mutation confers resistance to ciprofloxacin only. If G81D and D82G are present simultaneously, there is also nalidixic acid resistance	gyrA_1_CP073768.1_D82G
gyrA_1_CP073768.1	AA	ASP-82	82	GAC	D	G	Quinolone	Ciprofloxacin	8980760	Target modification	D82G mutation confers resistance to ciprofloxacin only. If D82G and G81D are present simultaneously, there is also nalidixic acid resistance
gyrA_1_CP073768.1	AA	ASP-82	82	GAC	D	G	Quinolone	Nalidixic acid,Ciprofloxacin	8980760	Target modification	D82G mutation confers resistance to ciprofloxacin only. If D82G and G81D are present simultaneously, there is also nalidixic acid resistance	gyrA_1_CP073768.1_G81D
gyrA_1_CP073768.1	AA	SER-83	83	TCG	S	L,W,A,V	Quinolone	Nalidixic acid,Ciprofloxacin	8891148,2168148,12654733,12654733	Target modification
gyrA_1_CP073768.1	AA	ALA-84	84	GCG	A	P,V	Quinolone	Nalidixic acid,Ciprofloxacin	11451702,7840592	Target modification	Unknown phenotype if A84P or A84V occur alone. Nalidixic acid and ciprofloxacin resistance when associated with other gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
gyrA_1_CP073768.1	AA	ASP-87	87	GAC	D	N,G,Y,A,H,V	Quinolone	Nalidixic acid	12654733,12654733,12654733,22878251,12654733,1850972	Target modification	D87G or D87Y confer resistance to nalidixic acid only, if occurring alone. Unknown phenotype if D87H occurs alone
gyrA_1_CP073768.1	AA	ASP-87	87	GAC	D	N,G,Y,A,H,V	Quinolone	Nalidixic acid,Ciprofloxacin	12654733,12654733,12654733,22878251,12654733,1850972	Target modification	D87G or D87Y confer resistance to nalidixic acid only, if occurring alone. Unknown phenotype if D87H occurs alone	gyrA_1_CP073768.1_S83L.W.A.V
gyrA_1_CP073768.1	AA	GLN-106	106	CAG	Q	H,R	Quinolone	Nalidixic acid,Ciprofloxacin	2168148,1850970	Target modification	Unknown phenotype if Q106H occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with other gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
gyrA_1_CP073768.1	AA	ALA-196	196	GCG	A	E	Quinolone	Nalidixic acid,Ciprofloxacin	14506034	Target modification	Unknown phenotype if A196E occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with other gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
gyrB_1_CP047010.1	AA	ASP-426	426	GAC	D	N	Quinolone	Nalidixic acid,Ciprofloxacin	1656869	Target modification
gyrB_1_CP047010.1	AA	LYS-447	447	AAG	K	E	Quinolone	Nalidixic acid	1656869	Target modification
parC_1_CP084529.1	AA	ALA-56	56	GCC	A	T	Quinolone	Nalidixic acid,Ciprofloxacin	12654733	Target modification
parC_1_CP084529.1	AA	SER-57	57	AGC	S	T	Quinolone	Nalidixic acid,Ciprofloxacin	14510643	Target modification	Unknown phenotype if S57T occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parC_1_CP084529.1	AA	PHE-60	60	TTT	F	I,K	Quinolone	Nalidixic acid,Ciprofloxacin	18500921,1850092	Target modification	Unknown phenotype if F60I or F60K occur alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parC_1_CP084529.1	AA	GLY-78	78	GGC	G	D,C	Quinolone	Nalidixic acid,Ciprofloxacin	8851598,14510643	Target modification	Unknown phenotype if G78C occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parC_1_CP084529.1	AA	SER-80	80	AGC	S	R,I,W,L	Quinolone	Nalidixic acid,Ciprofloxacin	8851598,8851598,21856834-20638608,8524852,25631675,25631675,25631675	Target modification	Unknown phenotype if each mutation occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parC_1_CP084529.1	AA	GLU-84	84	GAA	E	G,K,V,A,R	Quinolone	Nalidixic acid,Ciprofloxacin	12654733,8524852,12654733,20638608,20638608	Target modification	Unknown phenotype if each mutation occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parC_1_CP084529.1	AA	ALA-108	108	GCN	A	V,T		Unknown	12523629,18500921	Target modification
parE_1_CP034658.1	AA	ILE-355	355	ATC	I	T	Quinolone	Nalidixic acid,Ciprofloxacin	28598203	Target modification	Unknown phenotype if I355T occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	LEU-416	416	CTT	L	F	Quinolone	Nalidixic acid,Ciprofloxacin	14510643	Target modification	Unknown phenotype if L416F occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	GLY-423	423	GGC	G	R	Quinolone	Nalidixic acid,Ciprofloxacin	18500921	Target modification	Unknown phenotype if G423R occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	PRO-439	439	CCA	P	S	Quinolone	Nalidixic acid,Ciprofloxacin	18500921	Target modification	Unknown phenotype if P439S occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	ILE-444	444	ATC	I	F	Quinolone	Nalidixic acid,Ciprofloxacin	14506034	Target modification	Unknown phenotype if I444F occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	LEU-445	445	CTT	L	H	Quinolone	Nalidixic acid,Ciprofloxacin	8980775	Target modification
parE_1_CP034658.1	AA	SER-458	458	TCG	S	T,A	Quinolone	Nalidixic acid,Ciprofloxacin	14506034,28598203	Target modification	Unknown phenotype if S458T or S458A occur alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	GLU-460	460	GAA	E	D	Quinolone	Nalidixic acid,Ciprofloxacin	14510643	Target modification	Unknown phenotype if E460D occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	ILE-464	464	ATT	I	F	Quinolone	Nalidixic acid,Ciprofloxacin	14510643	Target modification	Unknown phenotype if I464F occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	ILE-470	470	ATC	I	M	Quinolone	Nalidixic acid,Ciprofloxacin	18500921	Target modification	Unknown phenotype if I470M occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	ASP-476	476	GAT	D	N	Quinolone	Nalidixic acid,Ciprofloxacin	25631675	Target modification	Unknown phenotype if D476N occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations	gyrA_1_CP073768.1_S83L.W.A.V
parE_1_CP034658.1	AA	ILE-529	529	ATT	I	L	Quinolone	Nalidixic acid,Ciprofloxacin	14506034	Target modification	Unknown phenotype if I529L occurs alone. Nalidixic acid and ciprofloxacin resistance when associated with gyrA mutations.	gyrA_1_CP073768.1_S83L.W.A.V
pmrA_1_CP047010.1	AA	SER-39	39	AGC	S	I	Polymyxin	Colistin	25150146	Target modification	Phenotype described when S39I and R81S occur simultaneously	pmrA_1_CP047010.1_S39I,pmrA_1_CP047010.1_R81S
pmrA_1_CP047010.1	AA	ARG-81	81	CGC	R	S	Polymyxin	Colistin	25150146	Target modification	Phenotype described when S39I and R81S occur simultaneously	pmrA_1_CP047010.1_S39I,pmrA_1_CP047010.1_R81S
pmrB_1_CP072802.1	AA	VAL-161	161	GTG	V	G	Polymyxin	Colistin	25150146	Target modification
folP_1_CP047010	AA	PHE-28	28	TTT	F	L,I	Folate pathway antagonist	Sulfamethoxazole	1522070,7642493
folP_1_CP047010	AA	PRO-64	64	CCA	P	S	Folate pathway antagonist	Sulfamethoxazole	9449266
rpoB_1_CP047010.1	AA	VAL-146	146	GTT	V	F	Rifampicin	Rifampicin	3050121	Target modification
rpoB_1_CP047010.1	AA	GLN-513	513	CAG	Q	L,P	Rifampicin	Rifampicin	3050121	Target modification
rpoB_1_CP047010.1	AA	HIS-526	526	CAC	H	Y	Rifampicin	Rifampicin	3050121	Target modification
rpoB_1_CP047010.1	AA	ARG-529	529	CGT	R	C,S	Rifampicin	Rifampicin	3050121	Target modification
rpoB_1_CP047010.1	AA	SER-531	531	TCC	S	F	Rifampicin	Rifampicin	3050121	Target modification
rpoB_1_CP047010.1	AA	LEU-533	533	CTC	L	P	Rifampicin	Rifampicin	3050121	Target modification
rpoB_1_CP047010.1	AA	THR-563	563	ACC	T	P	Rifampicin	Rifampicin	3050121	Target modification
rpoB_1_CP047010.1	AA	PRO-564	564	CCT	P	L	Rifampicin	Rifampicin	3050121	Target modification
rpoB_1_CP047010.1	AA	ILE-572	572	ATC	I	L,F,N	Rifampicin	Rifampicin	23433244	Target modification
rpoB_1_CP047010.1	AA	ARG-687	687	CGT	R	H	Rifampicin	Rifampicin	3050121	Target modification
23S_1_CP053604.1	NUC	THR-754	754	T	T	A	Macrolide	Erythromycin,Telithromycin	10027979	Target modification
23S_1_CP053604.1	NUC	GLY-2032	2032	G	G	A,T,C	Oxazolidinone	Linezolid	10986233	Target modification
23S_1_CP053604.1	NUC	ALA-2058	2058	A	A	G	Macrolide	Erythromycin,Azithromycin,Telithromycin	15616307	Target modification
23S_1_CP053604.1	NUC	GLY-2447	2447	G	G	T	Oxazolidinone	Linezolid	10986233	Target modification
23S_1_CP053604.1	NUC	THR-2609	2609	T	T	C	Macrolide	Telithromycin	11698379	Target modification
16S-rrsB_1_CP067250.1	NUC	ALA-523	523	A	A	C	Aminoglycoside	Streptomycin	3054810	Interference with drug-induced conformational modification
16S-rrsB_1_CP067250.1	NUC	GLY-1058	1058	G	G	C	Tetracycline	Tetracycline,  Doxycycline, Minocycline, Tigecycline	14985271	Target modification	Tigecycline borderline resistance
16S-rrsB_1_CP067250.1	NUC	GLY-1064	1064	G	G	T,C,A	Aminoglycoside	Spectinomycin	8127669,8127669,8127669	Target modification
16S-rrsB_1_CP067250.1	NUC	CYS-1066	1066	C	C	T	Aminoglycoside	Spectinomycin	7885842	Target modification
16S-rrsB_1_CP067250.1	NUC	THR-1406	1406	T	T	A	Aminoglycoside	G418, Gentamicin C, Kanamycin A, Tobramycin 	11502507	Target modification
16S-rrsB_1_CP067250.1	NUC	ALA-1408	1408	A	A	G	Aminoglycoside	Gentamicin C, Kanamycin A, Neomycin, Paromomycin	11502507	Target modification
16S-rrsC_1_CP053603.1	NUC	ALA-794	794	A	A	G,T	Aminoglycoside	Kasugamycin	10512710,10512710	Target modification
16S-rrsC_1_CP053603.1	NUC	GLY-926	926	G	G	A,C,T	Aminoglycoside	Kasugamycin	10512710,10512710,10512710	Target modification
16S-rrsC_1_CP053603.1	NUC	ALA-1519	1519	A	A	G,C,T	Aminoglycoside	Kasugamycin	10512710,10512710,10512710	Target modification
16S-rrsB_1_CP067250.1	NUC	CYS-1192	1192	C	C	T,G,A	Aminoglycoside	Spectinomycin	2447957,2447957,2447957	Target modification
16S-rrsH_1_CP053603.1	NUC	CYS-1192	1192	C	C	T	Aminoglycoside	Spectinomycin	6330677	Target modification
ampC-promoter-size-53bp_1_CP037449.1	NUC	CYS--42	-42	C	C	T,A,G	Beta-lactam	Ampicillin, Ampicillin+clavulanic acid, Amoxicillin, Amoxicillin+clavulanic acid, Cefixime, Cefotaxime, Cefoxitin, Ceftazidime, Piperacillin	21653764,21653764,21653764	Enzymatic degradation
ampC-promoter-size-53bp_1_CP037449.1	NUC	THR--32	-32	T	T	A,G,C	Beta-lactam	Ampicillin, Ampicillin+clavulanic acid, Amoxicillin, Amoxicillin+clavulanic acid, Cefixime, Cefotaxime, Cefoxitin, Ceftazidime, Piperacillin	21653764,21653764,21653764	Enzymatic degradation
# Indels			-9.22337203685478E+018
ampC-promoter-size-53bp_1_CP037449.1	NUC		-13	-	ins	GT,G	Beta-lactam	Ampicillin, Ampicillin+clavulanic acid, Amoxicillin, Amoxicillin+clavulanic acid, Cefixime, Cefotaxime, Cefoxitin, Ceftazidime, Piperacillin	21653764, 21653764	Enzymatic degradation
ampC-promoter-size-53bp_1_CP037449.1	NUC		-14	-	ins	GT	Beta-lactam	Ampicillin, Ampicillin+clavulanic acid, Amoxicillin, Amoxicillin+clavulanic acid, Cefixime, Cefotaxime, Cefoxitin, Ceftazidime, Piperacillin	21653764	Enzymatic degredation	Annotated in litteratur as -13insGT. Neighbouring GT position makes it impossible to determine which GT pair has been inserted, hence -13insGT is identical to -14/-16insGT and -15insTG.
ampC-promoter-size-53bp_1_CP037449.1	NUC		-15	-	ins	TG	Beta-lactam	Ampicillin, Ampicillin+clavulanic acid, Amoxicillin, Amoxicillin+clavulanic acid, Cefixime, Cefotaxime, Cefoxitin, Ceftazidime, Piperacillin	21653764	Enzymatic degredation	Annotated in litteratur as -13insGT. Neighbouring GT position makes it impossible to determine which GT pair has been inserted, hence -13insGT is identical to -14/-16insGT and -15insTG.
ampC-promoter-size-53bp_1_CP037449.1	NUC		-16	-	ins	GT	Beta-lactam	Ampicillin, Ampicillin+clavulanic acid, Amoxicillin, Amoxicillin+clavulanic acid, Cefixime, Cefotaxime, Cefoxitin, Ceftazidime, Piperacillin	21653764	Enzymatic degredation	Annotated in litteratur as -13insGT. Neighbouring GT position makes it impossible to determine which GT pair has been inserted, hence -13insGT is identical to -14/-16insGT and -15insTG.
